Dual Immunotherapeutic Agents Improve Outcomes in Melanoma

Use of two agents that stimulate the immune system, nivolumab and ipilimumab, appear to provide improved outcomes compared to standard therapy among patients with melanoma that has spread to the brain.

A trial evaluated the effectiveness of nivolumab plus ipilimumab among patients with melanoma that had spread to the brain (brain metastases) who had not received prior therapy for their brain metastases. Results demonstrated that the combination of nivolumab plus ipilimumab provided impressive results when compared to historical standards for this group of patients.
The article from the New England Journal of Medicine can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa1805453?query=featured_home

Leave a Reply

Your email address will not be published. Required fields are marked *